» Authors » Dustin R Wakeman

Dustin R Wakeman

Explore the profile of Dustin R Wakeman including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 21
Citations 1362
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Marmion D, Deng P, Hiller B, Lewis R, Harms L, Cameron D, et al.
Biology (Basel) . 2025 Feb; 14(2). PMID: 40001985
The transplantation of human neurons into the central nervous system (CNS) offers transformative opportunities for modeling neurodegenerative diseases in vivo. This study evaluated the survival, integration, and functional properties of...
2.
Wakeman D, Weed M, Perez S, Cline E, Viola K, Wilcox K, et al.
Neuropathol Appl Neurobiol . 2022 Feb; 48(4):e12800. PMID: 35156715
Aims: An obstacle to developing new treatment strategies for Alzheimer's disease (AD) has been the inadequate translation of findings in current AD transgenic rodent models to the prediction of clinical...
3.
Manfredsson F, Polinski N, Subramanian T, Boulis N, Wakeman D, Mandel R
Front Aging Neurosci . 2020 Dec; 12:593572. PMID: 33364933
No abstract available.
4.
Lee J, Zhang R, Yan M, Duggineni S, Wakeman D, Niles W, et al.
Proc Natl Acad Sci U S A . 2020 Nov; 117(49):31177-31188. PMID: 33219123
A transplanted stem cell's engagement with a pathologic niche is the first step in its restoring homeostasis to that site. Inflammatory chemokines are constitutively produced in such a niche; their...
5.
Hiller B, Marmion D, Gross R, Thompson C, Chavez C, Brundin P, et al.
Stem Cells Transl Med . 2020 Sep; 10(2):278-290. PMID: 32997443
Nongenetic methodologies to reduce undesirable proliferation would be valuable when generating dopamine neurons from stem cells for transplantation in Parkinson's disease (PD). To this end, we modified an established method...
6.
Hartman R, Nathan N, Ghosh N, Pernia C, Law J, Nuryyev R, et al.
Cell Rep . 2020 May; 31(6):107622. PMID: 32402283
To date, no stem cell therapy has been directed to specific recipients-and, conversely, withheld from others-based on a clinical or molecular profile congruent with that cell's therapeutic mechanism-of-action (MOA) for...
7.
Wakeman D, Hiller B, Marmion D, McMahon C, Corbett G, Mangan K, et al.
Stem Cell Reports . 2017 Jun; 9(1):149-161. PMID: 28579395
A major challenge for clinical application of pluripotent stem cell therapy for Parkinson's disease (PD) is large-scale manufacturing and cryopreservation of neurons that can be efficiently prepared with minimal manipulation....
8.
9.
Olanow C, Wakeman D, Kordower J
Mov Disord . 2014 Jul; 29(8):963-6. PMID: 25043799
No abstract available.
10.
Wakeman D, Kordower J
J Comp Neurol . 2014 Jun; 522(12):2689-90. PMID: 24942075
No abstract available.